Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review
Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis and staging of lung cancer, but is also appealing for assessment of prognosis and treatment. A systematic search of the published work shows good evidence that [18F]FDG uptake on PET has independent prognostic...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2004-09, Vol.5 (9), p.531-540 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 540 |
|---|---|
| container_issue | 9 |
| container_start_page | 531 |
| container_title | The lancet oncology |
| container_volume | 5 |
| creator | Vansteenkiste, Johan Fischer, Barbara M Dooms, Christophe Mortensen, Jann |
| description | Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis and staging of lung cancer, but is also appealing for assessment of prognosis and treatment. A systematic search of the published work shows good evidence that [18F]FDG uptake on PET has independent prognostic value in newly diagnosed nonsmall- cell lung cancer. PET is a sensitive method of measuring the biological effects of anticancer therapy, but until better standardisation and large-scale experience is available, it should only be used for additional assessments of early response in clinical trials. Further studies are needed to define the role of [18F]FDG-PET in restaging after induction therapy in multimodality approaches for locally advanced lung cancer. The assessment of prognosis by [18F]FDG-PET is less substantiated in treated lung cancer than in newly diagnosed patients. Good prospective evidence documents the effectiveness of [18F]FDG-PET over CT in the correct identification of recurrent lung cancer. |
| doi_str_mv | 10.1016/S1470-2045(04)01564-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66828455</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204504015645</els_id><sourcerecordid>66828455</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-b9c14a414fdf4f49b70e6d71ce46694c0c3b5630be31c576090665d42feabe8d3</originalsourceid><addsrcrecordid>eNqFkV9rFTEQxYNYbK1-BCUoiH1YnexOsru-iBStQkFBfQ7Z7Oxtyt3kNsla7rc39w8IgviUSfLLzMk5jD0T8EaAUG-_C2yhqgHla8ALEFJhJR-ws3JcCuy6h_v6gJyyxyndAohWgHzEToVsmha7-oytvoXkcgy-otml5ILnOcxhFc3mZsud55sYVj6k7Cw3fuT5hsoVLft9SpTSTD7zMPH14lfcGm8pvuNpmzLNZkdF-uXo_gk7mcw60dPjes5-fvr44_Jzdf316svlh-vKFjm5Gnor0KDAaZxwwn5ogdTYCkuoVI8WbDNI1cBAjbCyVdCDUnLEeiIzUDc25-zVoW_RfbdQyrp8y9J6bTyFJWmlurpDKQv48i_wNizRF226BtW22MuuK9SLf1PQC4VtXSB5gGwMKUWa9Ca62cStFqB3Yel9WHqXhAbU-7D0TsLzY_NlmGn88-qYTgHeHwAqjhUXo07WUXF4dJFs1mNw_xnxG486pKQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>200916472</pqid></control><display><type>article</type><title>Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Vansteenkiste, Johan ; Fischer, Barbara M ; Dooms, Christophe ; Mortensen, Jann</creator><creatorcontrib>Vansteenkiste, Johan ; Fischer, Barbara M ; Dooms, Christophe ; Mortensen, Jann</creatorcontrib><description>Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis and staging of lung cancer, but is also appealing for assessment of prognosis and treatment. A systematic search of the published work shows good evidence that [18F]FDG uptake on PET has independent prognostic value in newly diagnosed nonsmall- cell lung cancer. PET is a sensitive method of measuring the biological effects of anticancer therapy, but until better standardisation and large-scale experience is available, it should only be used for additional assessments of early response in clinical trials. Further studies are needed to define the role of [18F]FDG-PET in restaging after induction therapy in multimodality approaches for locally advanced lung cancer. The assessment of prognosis by [18F]FDG-PET is less substantiated in treated lung cancer than in newly diagnosed patients. Good prospective evidence documents the effectiveness of [18F]FDG-PET over CT in the correct identification of recurrent lung cancer.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(04)01564-5</identifier><identifier>PMID: 15337482</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aged ; Aged, 80 and over ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - diagnostic imaging ; Cellular biology ; Chemotherapy ; Clinical trials ; Enzymes ; Fluorodeoxyglucose F18 ; Histology ; Humans ; Induction therapy ; Lung cancer ; Lung Neoplasms - diagnostic imaging ; Medical imaging ; Medical prognosis ; Metabolism ; Middle Aged ; Neoplasm Recurrence, Local - diagnostic imaging ; Patients ; Positron emission tomography ; Prognosis ; Sensitivity and Specificity ; Survival analysis ; Tomography ; Tomography, Emission-Computed ; Tomography, X-Ray Computed</subject><ispartof>The lancet oncology, 2004-09, Vol.5 (9), p.531-540</ispartof><rights>2004 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Sep 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-b9c14a414fdf4f49b70e6d71ce46694c0c3b5630be31c576090665d42feabe8d3</citedby><cites>FETCH-LOGICAL-c482t-b9c14a414fdf4f49b70e6d71ce46694c0c3b5630be31c576090665d42feabe8d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2067749588?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15337482$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vansteenkiste, Johan</creatorcontrib><creatorcontrib>Fischer, Barbara M</creatorcontrib><creatorcontrib>Dooms, Christophe</creatorcontrib><creatorcontrib>Mortensen, Jann</creatorcontrib><title>Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis and staging of lung cancer, but is also appealing for assessment of prognosis and treatment. A systematic search of the published work shows good evidence that [18F]FDG uptake on PET has independent prognostic value in newly diagnosed nonsmall- cell lung cancer. PET is a sensitive method of measuring the biological effects of anticancer therapy, but until better standardisation and large-scale experience is available, it should only be used for additional assessments of early response in clinical trials. Further studies are needed to define the role of [18F]FDG-PET in restaging after induction therapy in multimodality approaches for locally advanced lung cancer. The assessment of prognosis by [18F]FDG-PET is less substantiated in treated lung cancer than in newly diagnosed patients. Good prospective evidence documents the effectiveness of [18F]FDG-PET over CT in the correct identification of recurrent lung cancer.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</subject><subject>Cellular biology</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Enzymes</subject><subject>Fluorodeoxyglucose F18</subject><subject>Histology</subject><subject>Humans</subject><subject>Induction therapy</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Patients</subject><subject>Positron emission tomography</subject><subject>Prognosis</subject><subject>Sensitivity and Specificity</subject><subject>Survival analysis</subject><subject>Tomography</subject><subject>Tomography, Emission-Computed</subject><subject>Tomography, X-Ray Computed</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkV9rFTEQxYNYbK1-BCUoiH1YnexOsru-iBStQkFBfQ7Z7Oxtyt3kNsla7rc39w8IgviUSfLLzMk5jD0T8EaAUG-_C2yhqgHla8ALEFJhJR-ws3JcCuy6h_v6gJyyxyndAohWgHzEToVsmha7-oytvoXkcgy-otml5ILnOcxhFc3mZsud55sYVj6k7Cw3fuT5hsoVLft9SpTSTD7zMPH14lfcGm8pvuNpmzLNZkdF-uXo_gk7mcw60dPjes5-fvr44_Jzdf316svlh-vKFjm5Gnor0KDAaZxwwn5ogdTYCkuoVI8WbDNI1cBAjbCyVdCDUnLEeiIzUDc25-zVoW_RfbdQyrp8y9J6bTyFJWmlurpDKQv48i_wNizRF226BtW22MuuK9SLf1PQC4VtXSB5gGwMKUWa9Ca62cStFqB3Yel9WHqXhAbU-7D0TsLzY_NlmGn88-qYTgHeHwAqjhUXo07WUXF4dJFs1mNw_xnxG486pKQ</recordid><startdate>200409</startdate><enddate>200409</enddate><creator>Vansteenkiste, Johan</creator><creator>Fischer, Barbara M</creator><creator>Dooms, Christophe</creator><creator>Mortensen, Jann</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200409</creationdate><title>Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review</title><author>Vansteenkiste, Johan ; Fischer, Barbara M ; Dooms, Christophe ; Mortensen, Jann</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-b9c14a414fdf4f49b70e6d71ce46694c0c3b5630be31c576090665d42feabe8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</topic><topic>Cellular biology</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Enzymes</topic><topic>Fluorodeoxyglucose F18</topic><topic>Histology</topic><topic>Humans</topic><topic>Induction therapy</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Patients</topic><topic>Positron emission tomography</topic><topic>Prognosis</topic><topic>Sensitivity and Specificity</topic><topic>Survival analysis</topic><topic>Tomography</topic><topic>Tomography, Emission-Computed</topic><topic>Tomography, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vansteenkiste, Johan</creatorcontrib><creatorcontrib>Fischer, Barbara M</creatorcontrib><creatorcontrib>Dooms, Christophe</creatorcontrib><creatorcontrib>Mortensen, Jann</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vansteenkiste, Johan</au><au>Fischer, Barbara M</au><au>Dooms, Christophe</au><au>Mortensen, Jann</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2004-09</date><risdate>2004</risdate><volume>5</volume><issue>9</issue><spage>531</spage><epage>540</epage><pages>531-540</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><coden>LANCAO</coden><abstract>Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis and staging of lung cancer, but is also appealing for assessment of prognosis and treatment. A systematic search of the published work shows good evidence that [18F]FDG uptake on PET has independent prognostic value in newly diagnosed nonsmall- cell lung cancer. PET is a sensitive method of measuring the biological effects of anticancer therapy, but until better standardisation and large-scale experience is available, it should only be used for additional assessments of early response in clinical trials. Further studies are needed to define the role of [18F]FDG-PET in restaging after induction therapy in multimodality approaches for locally advanced lung cancer. The assessment of prognosis by [18F]FDG-PET is less substantiated in treated lung cancer than in newly diagnosed patients. Good prospective evidence documents the effectiveness of [18F]FDG-PET over CT in the correct identification of recurrent lung cancer.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>15337482</pmid><doi>10.1016/S1470-2045(04)01564-5</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2004-09, Vol.5 (9), p.531-540 |
| issn | 1470-2045 1474-5488 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66828455 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Aged Aged, 80 and over Cancer therapies Carcinoma, Non-Small-Cell Lung - diagnostic imaging Cellular biology Chemotherapy Clinical trials Enzymes Fluorodeoxyglucose F18 Histology Humans Induction therapy Lung cancer Lung Neoplasms - diagnostic imaging Medical imaging Medical prognosis Metabolism Middle Aged Neoplasm Recurrence, Local - diagnostic imaging Patients Positron emission tomography Prognosis Sensitivity and Specificity Survival analysis Tomography Tomography, Emission-Computed Tomography, X-Ray Computed |
| title | Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A25%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Positron-emission%20tomography%20in%20prognostic%20and%20therapeutic%20assessment%20of%20lung%20cancer:%20systematic%20review&rft.jtitle=The%20lancet%20oncology&rft.au=Vansteenkiste,%20Johan&rft.date=2004-09&rft.volume=5&rft.issue=9&rft.spage=531&rft.epage=540&rft.pages=531-540&rft.issn=1470-2045&rft.eissn=1474-5488&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1470-2045(04)01564-5&rft_dat=%3Cproquest_cross%3E66828455%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=200916472&rft_id=info:pmid/15337482&rft_els_id=S1470204504015645&rfr_iscdi=true |